Targeting the intestinal L-cell for obesity and type 2 diabetes treatment

Research output: Contribution to journalJournal articleResearchpeer-review

Degradation-resistant glucagon-like peptide-1 (GLP-1) mimetics and GLP-1 enhancers (inhibitors of dipeptidyl peptidase-4, the enzyme which degrades and inactivates GLP-1) have been used for treatment of type 2 diabetes mellitus since 2005-2006. Cutting-edge research is now focusing on uncovering the secretory mechanisms of the GLP-1-producing cells (L-cells) with the purpose of developing agonists that enhance endogenous hormone secretion. Since GLP-1 co-localizes with other anorectic peptides, cholecystokinin, oxyntomodulin/glicentin and peptide YY, L-cell targeting might cause release of several hormones at the same time, providing additive effects on appetite and glucose regulation. In this review, we explore the role of proglucagon-derived peptides and other L-cell co-localizing hormones, in appetite regulation and the mechanism regulating their secretion.

Original languageEnglish
JournalExpert Review of Endocrinology & Metabolism
Issue number1
Pages (from-to)61-72
Number of pages12
Publication statusPublished - 1 Jan 2014

    Research areas

  • appetite regulation, gut hormones, gut-brain axis, L-cell, obesity

ID: 129244994